Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more
Apex Biotechnology Corp (1733) - Total Assets
Latest total assets as of September 2025: NT$2.31 Billion TWD
Based on the latest financial reports, Apex Biotechnology Corp (1733) holds total assets worth NT$2.31 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Apex Biotechnology Corp - Total Assets Trend (2002–2024)
This chart illustrates how Apex Biotechnology Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Apex Biotechnology Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Apex Biotechnology Corp's total assets of NT$2.31 Billion consist of 67.9% current assets and 32.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 22.0% |
| Accounts Receivable | NT$354.72 Million | 14.7% |
| Inventory | NT$662.49 Million | 27.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$39.60 Million | 1.6% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Apex Biotechnology Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apex Biotechnology Corp's current assets represent 67.9% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 22.0% of total assets in 2024, up from 1.5% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 27.4% of total assets.
Apex Biotechnology Corp Competitors by Total Assets
Key competitors of Apex Biotechnology Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Apex Biotechnology Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Apex Biotechnology Corp generates 0.77x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Apex Biotechnology Corp generates $5.29 in net profit.
Apex Biotechnology Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.08 | 3.55 | 1.91 |
| Quick Ratio | 2.71 | 2.12 | 1.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.18 Billion | NT$ 1.12 Billion | NT$ 801.05 Million |
Apex Biotechnology Corp - Advanced Valuation Insights
This section examines the relationship between Apex Biotechnology Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.63 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 5.4% |
| Total Assets | NT$2.42 Billion |
| Market Capitalization | $65.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Apex Biotechnology Corp's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Apex Biotechnology Corp's assets grew by 5.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Apex Biotechnology Corp (2002–2024)
The table below shows the annual total assets of Apex Biotechnology Corp from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.42 Billion | +5.35% |
| 2023-12-31 | NT$2.30 Billion | -8.66% |
| 2022-12-31 | NT$2.51 Billion | -5.83% |
| 2021-12-31 | NT$2.67 Billion | +0.72% |
| 2020-12-31 | NT$2.65 Billion | -5.78% |
| 2019-12-31 | NT$2.81 Billion | +10.55% |
| 2018-12-31 | NT$2.55 Billion | -5.71% |
| 2017-12-31 | NT$2.70 Billion | +7.96% |
| 2016-12-31 | NT$2.50 Billion | -7.19% |
| 2015-12-31 | NT$2.69 Billion | +1.88% |
| 2014-12-31 | NT$2.64 Billion | -2.90% |
| 2013-12-31 | NT$2.72 Billion | -0.87% |
| 2012-12-31 | NT$2.75 Billion | +28.47% |
| 2011-12-31 | NT$2.14 Billion | +9.67% |
| 2010-12-31 | NT$1.95 Billion | +9.91% |
| 2009-12-31 | NT$1.77 Billion | +19.47% |
| 2008-12-31 | NT$1.49 Billion | -4.41% |
| 2007-12-31 | NT$1.55 Billion | +19.69% |
| 2006-12-31 | NT$1.30 Billion | +15.89% |
| 2005-12-31 | NT$1.12 Billion | +12.64% |
| 2004-12-31 | NT$994.56 Million | +3.12% |
| 2003-12-31 | NT$964.43 Million | +20.26% |
| 2002-12-31 | NT$801.97 Million | -- |